Cargando…
The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01
The α1-acid glycoprotein (AGP) is an abundant blood plasma protein with important immunomodulatory functions coupled to endogenous and exogenous ligand-binding properties. Its affinity for many drug-like structures, however, means AGP can have a significant effect on the pharmokinetics and pharmacod...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671939/ https://www.ncbi.nlm.nih.gov/pubmed/34758357 http://dx.doi.org/10.1016/j.jbc.2021.101392 |
_version_ | 1784615253150007296 |
---|---|
author | Landin, Erik J.B. Williams, Christopher Ryan, Sara A. Bochel, Alice Akter, Nahida Redfield, Christina Sessions, Richard B. Dedi, Neesha Taylor, Richard J. Crump, Matthew P. |
author_facet | Landin, Erik J.B. Williams, Christopher Ryan, Sara A. Bochel, Alice Akter, Nahida Redfield, Christina Sessions, Richard B. Dedi, Neesha Taylor, Richard J. Crump, Matthew P. |
author_sort | Landin, Erik J.B. |
collection | PubMed |
description | The α1-acid glycoprotein (AGP) is an abundant blood plasma protein with important immunomodulatory functions coupled to endogenous and exogenous ligand-binding properties. Its affinity for many drug-like structures, however, means AGP can have a significant effect on the pharmokinetics and pharmacodynamics of numerous small molecule therapeutics. Staurosporine, and its hydroxylated forms UCN-01 and UCN-02, are kinase inhibitors that have been investigated at length as antitumour compounds. Despite their potency, these compounds display poor pharmokinetics due to binding to both AGP variants, AGP1 and AGP2. The recent renewed interest in UCN-01 as a cytostatic protective agent prompted us to solve the structure of the AGP2–UCN-01 complex by X-ray crystallography, revealing for the first time the precise binding mode of UCN-01. The solution NMR suggests AGP2 undergoes a significant conformational change upon ligand binding, but also that it uses a common set of sidechains with which it captures key groups of UCN-01 and other small molecule ligands. We anticipate that this structure and the supporting NMR data will facilitate rational redesign of small molecules that could evade AGP and therefore improve tissue distribution. |
format | Online Article Text |
id | pubmed-8671939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-86719392021-12-22 The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 Landin, Erik J.B. Williams, Christopher Ryan, Sara A. Bochel, Alice Akter, Nahida Redfield, Christina Sessions, Richard B. Dedi, Neesha Taylor, Richard J. Crump, Matthew P. J Biol Chem Research Article The α1-acid glycoprotein (AGP) is an abundant blood plasma protein with important immunomodulatory functions coupled to endogenous and exogenous ligand-binding properties. Its affinity for many drug-like structures, however, means AGP can have a significant effect on the pharmokinetics and pharmacodynamics of numerous small molecule therapeutics. Staurosporine, and its hydroxylated forms UCN-01 and UCN-02, are kinase inhibitors that have been investigated at length as antitumour compounds. Despite their potency, these compounds display poor pharmokinetics due to binding to both AGP variants, AGP1 and AGP2. The recent renewed interest in UCN-01 as a cytostatic protective agent prompted us to solve the structure of the AGP2–UCN-01 complex by X-ray crystallography, revealing for the first time the precise binding mode of UCN-01. The solution NMR suggests AGP2 undergoes a significant conformational change upon ligand binding, but also that it uses a common set of sidechains with which it captures key groups of UCN-01 and other small molecule ligands. We anticipate that this structure and the supporting NMR data will facilitate rational redesign of small molecules that could evade AGP and therefore improve tissue distribution. American Society for Biochemistry and Molecular Biology 2021-11-07 /pmc/articles/PMC8671939/ /pubmed/34758357 http://dx.doi.org/10.1016/j.jbc.2021.101392 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Landin, Erik J.B. Williams, Christopher Ryan, Sara A. Bochel, Alice Akter, Nahida Redfield, Christina Sessions, Richard B. Dedi, Neesha Taylor, Richard J. Crump, Matthew P. The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 |
title | The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 |
title_full | The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 |
title_fullStr | The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 |
title_full_unstemmed | The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 |
title_short | The structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound UCN-01 |
title_sort | structural basis for high affinity binding of α1-acid glycoprotein to the potent antitumor compound ucn-01 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671939/ https://www.ncbi.nlm.nih.gov/pubmed/34758357 http://dx.doi.org/10.1016/j.jbc.2021.101392 |
work_keys_str_mv | AT landinerikjb thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT williamschristopher thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT ryansaraa thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT bochelalice thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT akternahida thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT redfieldchristina thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT sessionsrichardb thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT dedineesha thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT taylorrichardj thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT crumpmatthewp thestructuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT landinerikjb structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT williamschristopher structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT ryansaraa structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT bochelalice structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT akternahida structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT redfieldchristina structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT sessionsrichardb structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT dedineesha structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT taylorrichardj structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 AT crumpmatthewp structuralbasisforhighaffinitybindingofa1acidglycoproteintothepotentantitumorcompounducn01 |